| Literature DB >> 18253706 |
Hayato Tamai1, Hiroki Yamaguchi2, Hiroyuki Hamaguchi3, Fumiharu Yagasaki4, Masami Bessho4, Takeshi Kobayashi5, Hideki Akiyama5, Hisashi Sakamaki5, Satoshi Takahashi6, Arinobu Tojo6, Ken Ohmine7, Keiya Ozawa7, Hirokazu Okumura8, Shinji Nakao8, Ayako Arai9, Osamu Miura9, Shigeo Toyota10, Seiji Gomi11, Yoshiro Murai12, Noriko Usui13, Keisuke Miyazawa14, Kazuma Ohyashiki14, Naoto Takahashi15, Kenichi Sawada15, Atsushi Kato16, Kazuo Oshimi16, Koiti Inokuchi2, Kazuo Dan2.
Abstract
To clarify the clinical features of adult patients with acute leukemia (AL) with 11q23 abnormalities, we performed a retrospective analysis of data from 58 adult Japanese patients: 51 with acute myeloid leukemia (AML), and 7 with acute lymphoblastic leukemia (ALL). The incidences according to fusion partners in AML were: t(9;11), 31.3%; t(11;19), 27.4%; t(6;11), 21.5%. The incidence of patients with t(11;19) was higher than those in the US and Europe, and the incidence of t(4;11) was lower than that in childhood. The results indicated the poor prognosis of AML with 11q23 abnormalities regardless of the fusion partners. AML patients with 11q23 aged <60 years in the first CR who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) showed a more favorable outcome than those treated without allo-HSCT, although the differences were not statistically significant (P = 0.322 for DFS, P = 0.138 for OS). This result suggests that treatment strategies including allo-HSCT may be considered in the first CR in cases of AML with 11q23 abnormalities. However, further studies involving a large number of cases are required to assess the effect of allo-HSCT on adult AL with 11q23 abnormalities.Entities:
Mesh：
Year: 2008 PMID： 18253706 DOI： 10.1007/s12185-008-0034-2
Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490